Why the study?
There is a need for a cost-effective prognostic biomarker in HF beyond natriuretic peptides, particularly for congestion, and appropriate diuretic titration strategies remain unclear.
What is the role of carbohydrate antigen 125 (CA125) as a prognostic biomarker and guide for decongestion therapy in patients with heart failure?
What is the role of carbohydrate antigen 125 (CA125) as a prognostic biomarker and guide for decongestion therapy in patients with heart failure?
This review highlights the emerging role of CA125 as a cost-effective biomarker for prognosis and guiding diuretic therapy in heart failure.
Answers are grounded in this paper and cite their sources.
Highlights need for affordable congestion biomarkers beyond NPs in HF; leaves open optimal diuretic strategies pending RCTs.
Because heart failure (HF) is more lethal than some of the common malignancies in the general population, such as prostate cancer in men and breast cancer in women, there is a need for a cost-effective prognostic biomarker in HF beyond natriuretic peptides, especially concerning congestion, the most common reason for the hospitalisation of patients with worsening of HF. Furthermore, despite diuretics being the mainstay of treatment for volume overload in HF patients, no randomised trials have shown the mortality benefits of diuretics in HF patients, and appropriate diuretic titration strategies in this population are unclear. Recently, carbohydrate antigen (CA) 125, a well-established marker of ovarian cancer, emerged as both a prognostic indicator and a guide in tailoring decongestion therapy for patients with HF. Hence, in this review the authors present the molecular background regarding the role of CA125 in HF and address valuable clinical aspects regarding the relationship of CA125 with both prognosis and therapeutic management in HF.
No takes yet. Share an insight, caveat, or question.
Kumrić et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: